Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19275335 | 1.00 | FAAH (0.32) | FAAH | |
| SCHEMBL19270737 | 1.00 | FAAH (0.32) | FAAH | |
| SCHEMBL19270736 | 1.00 | FAAH (0.32) | FAAH | |
| SCHEMBL30886703 | 0.79 | POLB (0.31) | — | |
| SCHEMBL7522716 | 0.79 | POLB (0.31) | — | |
| SCHEMBL9450620 | 0.77 | KMT2A (0.40) | — | |
| SCHEMBL9450621 | 0.77 | KMT2A (0.40) | — | |
| SCHEMBL22911742 | 0.77 | KMT2A (0.40) | — | |
| SCHEMBL9450617 | 0.77 | KMT2A (0.40) | — | |
| SCHEMBL18227498 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191479-B1 | \"PROCESS FOR THE PREPARATION OF MACROCYCLIC KETONE ANALOGS OF HALICHONDRIN B OR PHARMACEUTICALLY ACCEPTABLE SALTS AND INTERMEDIATES THEREOF\ | CIPLA LTD (IN) | 2020-04-08 | — | — | EP | disclosed |
| EP-2949652-B1 | Intermediates for the preparation of halichondrin B | EISAI R&D MAN CO LTD (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-RE46965-E1 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-RE46965-E1 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170240561-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC KETONE ANALOGS OF HALICHONDRIN B OR PHARMACEUTICALLY ACCEPTABLE SALTS AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240561-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC KETONE ANALOGS OF HALICHONDRIN B OR PHARMACEUTICALLY ACCEPTABLE SALTS AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2017-08-24 | — | — | US | disclosed |
| US-9303050-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9303050-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-04-05 | — | — | US | disclosed |
| EP-2949652-A1 | Intermediates for the preparation of halichondrin B | Eisai R&D Management Co., Ltd. (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-20150232490-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| US-8445701-B2 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20120309988-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120309988-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2522663-A1 | Intermediates for the preparation of halichondrin B | Eisai R&D Management Co., Ltd. (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7982060-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7982060-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | EISAI CO., LTD (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | EISAI CO., LTD (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | CDK4, CCNB1, CDK14 | FAAH 4184/4885 |
| US-20170240561-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC KETONE ANALOGS OF HALICHONDRIN B OR PHARMACEUTICALLY ACCEPTABLE SALTS AND INTERMEDIATES THEREOF | HSD17B7, HKDC1, CYP8B1 | FAAH 3398/4885 |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | FAAH 3540/4885 |
| US-20120309988-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | ACVR1B, ACVR2B, BMP2 | FAAH 3651/4885 |
| US-20150232490-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | FAAH 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.